SiliconBeat

Bruce Peacock resigned today from the board of directors after serving less than two years there, where he also chaired its audit committee and was deemed its “financial expert” as defined by SEC rules. The resignation would leave the company with only two directors serving on its audit committee, a technical violation of a Nasdaq requirement that it be staffed by at least three independent directors.

Peacock, a venture partner at SV Life Sciences Advisers since Read the rest of this entry »

NeurogesX said Thursday that the European Medicines Agency’s committee for medicinal products for human use has recommended approval of Qutenza, the San Mateo biopharmaceutical’s treatment of peripheral neuropathic pain in non-diabetic adults.

The drug is delivered via Read the rest of this entry »